Advanced Robotic Techniques and Rapid Onsite Evaluation for Minimally Invasive Diagnosis and Next-Generation Sequencing.

NCT07685977 — Not applicable, Not yet recruiting, 400 participants, Vanderbilt University Medical Center

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Advanced Robotic Techniques and Rapid Onsite Evaluation for Minimally Invasive Diagnosis and Next-Generation Sequencing: the ARTEMIS Trial.

RegistryNCT07685977, acronym ARTEMIS
StatusNot yet recruiting
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: double, diagnostic
Enrollment400 (Estimated)
SponsorVanderbilt University Medical Center (Other); collaborators: AstraZeneca
ConditionsPeripheral Pulmonary Lesions (PPLs)
InterventionsRapid onsite evaluation (Other)
Datesstart 2026-10-01 (estimated), primary completion 2028-04-01 (estimated), completion 2029-04-01 (estimated), first posted 2026-07-06, last updated 2026-07-06
Locations8 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Peripheral Pulmonary Lesions (PPLs) All trials of Rapid onsite evaluation

-Summary

ARTEMIS is a multicenter randomized controlled trial. The goal is to understand whether rapid onsite evaluation during robotic assisted bronchoscopy improves the diagnostic performance of the procedure or not.

Expand all sections  ·  Collapse all

+Detailed description

Pulmonary nodules are an incredibly common finding, with millions incidentally detected in the US every year. Biopsy is often needed for diagnosis. Robotic assisted bronchoscopy (RAB) with integrated cone beam computed tomography (CBCT) has achieved diagnostic yields exceeding 80% in some studies, significantly higher than traditional methods without advanced imaging, due to the added ability to correct alignment of the bronchoscopy catheter with the target lesion in real-time. Given this, the added value of rapid on-site cytologic evaluation (ROSE) with modern bronchoscopy is an area of debate. ROSE involves immediate intraprocedural microscopic assessment of biopsy specimens (typically by a cytotechnologist) to confirm adequacy of biopsy samples for malignant diagnosis during the bronchoscopy. This study will aim to test the hypothesis that modern bronchoscopy done without ROSE guidance is non-inferior to bronchoscopy with ROSE available. Patients undergoing RAB to biopsy a lung lesion will be approached for enrollment and assigned to either ROSE vs no ROSE if they agree to participate. Randomization will be revealed before procedures are started. All decisions regarding procedure tools, techniques, and patient management will be per usual care and at the discretion of the treating physician.

+Arms and interventions

ArmTypeInterventionsDescription
Robotic assisted bronchoscopy with ROSEActive comparatorOther: Rapid onsite evaluationParticipants allocated to the robotic assisted bronchoscopy arm with rapid onsite evaluation will have ROSE available during the procedure
Robotic assisted bronchoscopy without ROSEActive comparatorOther: Rapid onsite evaluationParticipants allocated to the robotic assisted bronchoscopy arm without rapid onsite evaluation will not have ROSE available during the procedure
  • Rapid onsite evaluation (Other): ROSE involves immediate intraprocedural microscopic assessment of biopsy specimens (typically by a cytotechnologist) to confirm adequacy of biopsy samples for malignant diagnosis during the bronchoscopy

+Outcome measures

Primary outcomes

  • Strict diagnostic yield, defined as the proportion of procedures that result in acquisition of lesional tissue. [7 days post procedure]: Lesional tissue is defined by the presence of specific pathological findings that readily explain the presence of a pulmonary lesion. The following common pathological findings are pre-specified: 1. Malignancy 2. Specific benign pathologic findings including: organizing pneumonia, frank purulence/robust neutrophilic inflammation with a pathogen isolated, granulomatous inflammation, hamartoma, amyloidoma or other uncommon causes of peripheral pulmonary lesions with distinctive pathological patterns.

Secondary outcomes

  • Sufficiency of malignant specimens for Next-Generation Sequencing [30 days post procedure]: Proportion of malignant biopsies with sufficient material to send for NGS

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* ≥ 18 years of age at time of bronchoscopy
* Undergoing robotic assisted bronchoscopy to biopsy a pulmonary lesion

Exclusion Criteria:

* Declines to participate or inability to provide informed consent.
* Clinician determination that the use of ROSE is required or contraindicated for the optimal care of an individual patient
* Patient enrolled in another trial that requires ROSE for PPL biopsy
* Patient previously consented for this trial
* Pregnant or incarcerated patients

+Locations (8)

FacilityCityCountryStatus
Northwestern Memorial HospitalChicago, IllinoisUnited States
Rush University Medical CenterChicago, IllinoisUnited States
Johns Hopkins UniversityBaltimore, MarylandUnited States
Lahey Hospital and Medical CenterBurlington, MassachusettsUnited States
Memorial Sloan Kettering Cancer CenterNew York, New YorkUnited States
University of North Carolina Medical CenterChapel Hill, North CarolinaUnited States
Medical University of South CarolinaCharleston, South CarolinaUnited States
Vanderbilt University Medical CenterNashville, TennesseeUnited States

+Publications

  • Paez R, Lentz RJ, Duke JD, Siemann JK, Salmon C, Dahlberg GJ, Ratwani AP, Casey JD, Chen H, Chen SC, Shojaee S, Rickman OB, Gatto CL, Rice TW, Maldonado F. Robotic versus Electromagnetic Bronchoscopy for Peripheral Pulmonary Lesions: A Randomized Trial (RELIANT). Am J Respir Crit Care Med. 2025 Sep;211(9):1644-1651. doi: 10.1164/rccm.202409-1846OC. PMID 40460390
  • Avasarala SK, Matta M, Singh J, Bomeisl P, Michael CW, Young B, Panchabhai TS, Di Felice C, Dahlberg G, Maldonado F. Rapid On-site Evaluation Practice Variability Appraisal (ROSE PETAL) survey. Cancer Cytopathol. 2023 Feb;131(2):90-99. doi: 10.1002/cncy.22641. Epub 2022 Sep 1. PMID 36048711
  • Gonzalez AV, Silvestri GA, Korevaar DA, Gesthalter YB, Almeida ND, Chen A, Gilbert CR, Illei PB, Navani N, Pasquinelli MM, Pastis NJ, Sears CR, Shojaee S, Solomon SB, Steinfort DP, Maldonado F, Rivera MP, Yarmus LB. Assessment of Advanced Diagnostic Bronchoscopy Outcomes for Peripheral Lung Lesions: A Delphi Consensus Definition of Diagnostic Yield and Recommendations for Patient-centered Study Designs. An Official American Thoracic Society/American College of Chest Physicians Research Statement. Am J Respir Crit Care Med. 2024 Mar 15;209(6):634-646. doi: 10.1164/rccm.202401-0192ST. PMID 38394646
  • Lentz RJ, Frederick-Dyer K, Planz VB, Koyama T, Aboudara MC, Avasarala SK, Casey JD, Cheng GZ, D'Haese PF, Duke JD, Grogan EL, Hoopman TC, Johnson J, Katsis JM, Kurman JS, Low SW, Mahmood K, Rickman OB, Roller L, Salmon C, Shojaee S, Swanner B, Wahidi MM, Walston C, Silvestri GA, Yarmus L, Rahman NM, Maldonado F; Interventional Pulmonary Outcomes Group. Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules. N Engl J Med. 2025 Jun 5;392(21):2100-2112. doi: 10.1056/NEJMoa2414059. Epub 2025 May 18. PMID 40387025

+Investigators